Constellation Brings In Series B Totaling $22 Million, Including GSK Investment
This article was originally published in The Pink Sheet Daily
Executive SummaryInvolvement by GSK's venture arm SR One enables Constellation to keep pace with epigenetics competitor Epizyme, which is backed by Amgen and Astellas.
You may also be interested in...
For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.